Jon Kuehler
Mirati Therapeutics (United States)(US)
Publications by Year
Research Areas
Synthesis and Catalytic Reactions, Cancer-related gene regulation, HIV Research and Treatment, HIV/AIDS drug development and treatment, Protein Kinase Regulation and GTPase Signaling
Most-Cited Works
- → Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP -Deleted Cancers(2022)140 cited
- → Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction(2022)88 cited
- → Azaindole Hydroxamic Acids are Potent HIV-1 Integrase Inhibitors(2009)53 cited
- → Design and Synthesis of Novel N-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors(2011)43 cited
- → Azaindole N-methyl hydroxamic acids as HIV-1 integrase inhibitors-II. The impact of physicochemical properties on ADME and PK(2010)23 cited
- → Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein(2024)18 cited
- → Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors(2022)14 cited
- → Fragment optimization and elaboration strategies – the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits(2022)12 cited
- → Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography(2023)7 cited
- → Abstract LB505: Design and discovery of MRTX0902, a potent, selective, and orally bioavailable SOS1 inhibitor(2022)